News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Revenue from operations up 26% to Rs. 768 crores
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
The company increases its efficiency and is able to face the growing demand for its services.
Subscribe To Our Newsletter & Stay Updated
